

## 2023 Carbapenem Resistant Enterobacterales (CRE)/ Carbapenem Resistant A. baumannii (CRAB) Multi-site Gram-Negative Surveillance Initiative (MuGSI) Healthcare-Associated Infections Community Interface (HAIC) Case Report

Form Approved OMB No. 0920-0978

Patient's Name	2:			Phone no.:					
Address:					MRN:				
Address Type:					Hospital:				
		Ра	tient Identifier info	rmation is not transmitted to CDC					
DEMOGRAPH	ICS								
1. STATE:	2a. COUNTY:	2b. PLANNING REGION:	3. STATE ID:	4a. LABORATORY ID WHERE INCIDENT SPECIMEN IDENTIFIED:	4b. FACILITY ID WHERE PATIENT TREATED:				
5. DATE OF BIRT  6. AGE:  O Days		7. SEX AT BIRTH:  O Male O Female O Unknown  Check if transge	OHispanic o ONot Hispan OUnknown	or Latino American Indian or Alaminic or Latino Asian	ska Native				
9a. DATE OF INCIDENT SPECIMEN COLLECTION (DISC): (mm/dd/yyyy)  10. ORGANISM: OCRE				AB					
9b. TIME OF DIS	C: (HH:MM-Military Format)		If CRE, select one of the following:	O Escherichia coli O Enterobacter cloacae O Klebsiella aerogenes O Klebsiella oxytoca O Klebsiella pneumoniae					
☐ Blood ☐ Bone ☐ Bronchoalveola	ar lavage (CRAB only, com	plete Q23c)	(CR $\square$ Oth complete Q23c) (CR	ne und (specify):					
12. LOCATION (	F SPECIMEN COLLECT	ΓΙΟΝ:		13. WHERE WAS THE PATIENT LOCAT	TED ON THE 3RD CALENDAR DAY BEFORE THE DISC?				
OUTPATIENT Facility ID:	-	_	LTCF ility ID:	O Private residence O LTCF Facility ID:	OLTACH Facility ID:				
O Emergency room OICU OClinic/Doctor's office O Dialysis center O Surgery Observational/ Clinical decision unit O Other outpatient O Clenter on the control of the control				Hospital inpatient Facility ID:  Was the patient transferred from this hospital?  OYes ONo OUnknoo	OHomeless OIncarcerated OOther (specify): OUnknown				
		0	Unknown						
29 CALENDA O Yes	IENT HOSPITALIZED OF R DAYS AFTER THE DIS	SC? wn	ТНЕ	15a. WAS THE PATIENT IN AN ICU IN O Yes O No O Unknown IF YES, DATE OF ICU ADMISSION: (mm/dc  15b. WAS THE PATIENT IN AN ICU OI COLLECTION OR IN THE 6 DAYS O Yes O No O Unknown IF YES, DATE OF ICU ADMISSION: (mm/dc)	OR Date unknown  N THE DAY OF INCIDENT SPECIMEN  AFTER THE DISC?				
16. PATIENT OUT	COME: O Survived	<u> </u>		ODied	O Unknown				
DATE OF DISCHARGE: (mm/dd/yyyy) OR O Date unknown O Left against medical advice (AMA)  IF SURVIVED, DISCHARGED TO:				DATE OF DEATH: (mm/dd/yyyy) OR ☐ Date unknown  ON THE DAY OF OR IN THE 6 CALENDAR DAYS BEFORE DEATH, WAS THE PATHOGEN OF INTEREST ISOLATED FROM A SITE THAT MEETS THE CASE DEFINITION?					
O Private residence O Other (specify): OLTCF, Facility ID:				○ Yes ○ No ○ Unknow	'n				
OLTACH, Facil	ity ib		ted to average 28 minut	es per response including the time for revis	wing instructions searching existing data sources				

Public reporting burden of this collection of information is estimated to average 28 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

17a. TYPES OF INFECTION ASSO	CIATED WITH CULTURE(S): (Che	ck all that	apply):	ONo	ne	OColonized	O Unknow	n	_	
		_			_					
17b. RECURRENT UTI OYes	ONo OUnknown		17c. WAS 1	THE PATIENT TR	EATED FOR TH	E MUGSI ORGAN	NISM? OYes	O No O Unknow	/n	
18. UNDERLYING CONDITIONS:	(Check all that apply) O No	one	O Unknow	wn						
CHRONIC LUNG DISEASE	IMMUNOCOMPROMISED	CONDITI	ON		GIC CONDITION		SKIN CONDITIO	N		
☐ Cystic fibrosis☐ Chronic pulmonary disease	☐HIV infection ☐AIDS/CD4 count < 2	200		Cerebra	ıl palsy : cognitive defici		☐ Burn ☐ Decubitus/pr	roccuro ulcor		
CHRONIC METABOLIC DISEASE	Primary immunodefici			Demen		ı	Surgical wou			
Diabetes mellitus	Transplant, hematopoi		cell		y/seizure/seizure	e disorder		Other chronic ulcer or chronic wound		
☐With chronic complications	☐Transplant, solid organ	l		☐Multiple ☐Neurop			Other (specif	ther (specify):		
CARDIOVASCULAR DISEASE	Chronic liver disease			Parkins	on's disease		OTHER			
☐ CVA/Stroke/TIA☐ Congenital heart disease	Ascites			☐Other (	specify):		OTHER  Connective ti	ER onnective tissue disease		
Congestive heart failure	☐ Cirrhosis ☐ Hepatic encephalop	- a+b. /					Obesity or m			
☐ Myocardial infarction☐ Peripheral vascular disease (PVD	Usricaal blooding	Datriy		PLEGIAS/F	ARALYSIS		Pregnant			
GASTROINTESTINAL DISEASE	Hepatitis C			Hemipl	-		MuGSI CONDITI			
Diverticular disease	☐Treated, in SVR ☐Current, chronic			□Paraple □Quadri			Premature bi	problems/abnormalities rth		
Inflammatory bowel disease	MALIGNANCY			RENAL DIS						
☐ Peptic ulcer disease ☐ Short gut syndrome	Malignancy, hematolo				kidney disease					
	☐ Malignancy, solid orga ☐ Malignancy, solid orga				serum creatinine nown or not don					
19. SUBSTANCE USE SMOKING:	OTHER SUBSTANCES: (Check all th	at apply)	O None	O Unknown DUD/ ABUSE	MODE	OF DELIVERY (C	heck all that apply)			
(Check all that apply)	☐ Marijuana, cannabinoid (other than	cmokina)		DUD/ ABUSE			_	nknown		
None	Opioid, DEA schedule I (e.g., heroin	-		DUD or abuse				nknown		
☐ Unknown ☐ Tobacco	Opioid, DEA schedule II-IV (e.g., me		xycodone)	DUD or abuse	l		_	nknown		
E-nicotine delivery system	Opioid, NOS			DUD or abuse			_	nknown		
Marijuana	Cocaine			DUD or abuse	□ IDU □	Skin popping	□ Non-IDU □ Ur	nknown		
ALCOHOL ABUSE	Methamphetamine			DUD or abuse	□ IDU □	Skin popping	_	nknown		
O Yes O No	Other (specify):			DUD or abuse	□ IDU □	Skin popping	□ Non-IDU □ Ur	nknown		
OUnknown	Unknown substance			DUD or abuse	□ IDU □ Skin popping □ Non-IDU □ Unknown			nknown		
	DURING THE CURRENT HOSPITAL					STED TREATMENT	(MAT) FOR OPIOID	USE DISORDER?		
	OYes ONo ON/A (p	atient not	hospitalize	d or did not have	DUD)				_	
20. RISK FACTORS: (Check all tha	at apply) ONone O	Unknown	ı							
WAS INCIDENT SPECIMEN COLLECT DAYS AFTER HOSPITAL ADMISSION		O Yes	ONo				E ON THE DISC (UP	TO THE TIME OF DAR DAYS BEFORE DISC		
DATS AFTER HOSPITAL ADMISSION	v:	O ies	ONO			O No O Unkn		ANDAIS DEI ONE DISC		
PREVIOUS HOSPITALIZATION IN TH	IE YEAR BEFORE DISC	O Yes	ONo	OUnknown	-, -	HECK ALL THAT AI				
IF YES, DATE OF DISCHARGE CLOSEST TO DISC: (mm/dd/yyyy)			OR, D	ATE UNKNOWN		elling Urethral Cat pubic Catheter	heter			
Facility ID:	····				∟ зирга	ipubic Catrietei	□ottiei (st	becity).		
OVERNIGHT STAY IN LTCF IN THE Y	EAR BEFORE DISC:	O Yes	ONo	OUnknown	ANY OTHER	INDWELLING DE	VICE IN PLACE ON T	HE DISC UP TO THE TIME	-	
Facility ID:		-	_		OF COLLECT	TION), OR AT ANY	TIME IN THE 2 CALE	ENDAR DAYS BEFORE DISC		
OVERNIGHT STAY IN LTACH IN THE	YEAR BEFORE DISC:	O Yes	ONo	OUnknown	_	ONO OUnkn				
Facility ID:		•			IF YES, CF □ET/NT	HECK ALL THAT AP	PLY:  Tracheos	stomy		
SURGERY IN THE YEAR BEFORE DIS	C:	O Yes	O No	OUnknown	_	ostomy Tube	Nephros	•		
CURRENT CHRONIC DIALYSIS:		O Yes	Q No	OUnknown	☐ NG Tu	ıbe	☐Other (sp	pecify):		
IF YES, TYPE		<b>O</b> 1.23	<b>O</b>	<b>O</b> e					_	
OHemodialysis OPeritonea	•					_	FIONALLY IN THE YE	EAR BEFORE DISC:		
IF HEMODIALYSIS, TYPE OF VASCU O AV fistula/graft O Hemodia	_				-	O No O Unkn	own			
COUNTRY(IES):  CENTRAL LINE IN PLACE ON THE DISC (UP TO THE TIME										
OF COLLECTION), OR AT ANY TIME	•	O Yes	_	_					-	
DAYS BEFORE DISC:			O No	OUnknown	PATIENT HOSPITALIZED WHILE VISITING COUNTRY(IES) ABOVE:  O Yes  O No  O Unknown			KY(IES) ABOVE:		
	☐ Check here if cer	ntral line in	n place for >	2 calendar days	O res	JNO UNKN	OWII			
21a. WEIGHT:		21k	o. HEIGHT:				21c. BMI:			
lbs oz.	OR			ft in.	OR			_		
——— kg □Unknown				cm 🗆 Unknow	/n			Unknown		

22a. WAS THE URINE COLLECTED AN INDWELLING URETHRAL CATHOLOGY  O Yes  O No  O Unknown	THROUGH 22c. Pleas		ollowing sympto	ED WITH URINE CULTURE oms were reported during the 5 or the DISC.	day time period ir	ncluding the	2 calenda	ar
URINE CULTURES ONLY:	□No			Fever [temperature ≥ 100.4]		Symptoms fo	or patient	ts ≤ 1 year
22b. RECORD THE COLONY COUN		nknown ostovertebral angle pain	or tenderness	☐ Frequency ☐ Suprapubic tenderness		of age only: □Apnea	Г	Lethargy
		ysuria		Urgency		Bradycard		Vomiting
Complete questions 23a-23b ONLY 23a. DID THE PATIENT HAVE A SPIN THE 30 DAYS BEFORE THE DISC  Yes ONO OUnknown C  23b. RISK FACTORS IN THE 7 DAYS  Non-invasive positive pressure ver 7 calendar days before the DISC  Nebulizer treatment at any time in  Mechanical ventilation at any time  None	UTUM CULTURE POSITI C? O N/A S BEFORE THE DISC: ntilation (CPAP or BiPAP) at n the 7 calendar days befor	any time in the	non-LRT cult  23c. CHEST  Not done  No report  Acute resp  Air space of Ground gl  Bronchopi	estion 23c ONLY for A. BAUM/ ures where pneumonia is mar RADIOLOGY FINDINGS: (Ch available iratory distress syndrome (ARDS density/opacity ass opacities/infiltrates neumonia/pneumonia e out pneumonia	rked in question 1 leck all that apply Cavitatic Consolid S) Infiltrate Pleural ei Nodules	( <b>7a.</b> () on ation ffusion		or
24a. DID THE PATIENT HAVE A PC SARS-CoV-2 (MOLECULAR ASSAY, VIRAL TEST, EXCLUDING SEROLO BEFORE OR DAY OF THE DISC?  O Yes  O No  O Unknown	, ANTIGEN OR OTHER			MEN COLLECTION DATES FO S BEFORE OR DAY OF DISC:		TS IN		
O les O NO O Olikilowii								
			First positiv	e test:	or 🔲 Date unk	known		
			Most recent	positive	or	nown		
			test:					
25. WAS THE INCIDENT SPECIMEN O Yes O No O Unknown	N POLYMICROBIAL?			INCIDENT SPECIMEN TESTE	ED FOR CARBAPI	ENEMACE C		
26b. IF YES, WHAT TESTING METH	HOD WAS USED? (Check		O Yes	No OLaboratory not testing	g OUnknown		ENES?	
Non-Molecular Test Methods:		all that apply)					iENES?	
_	Molecular Test Method	11.77		D, WHAT WAS THE TESTING F			ENES?	
CarbaNP	Molecular Test Method	ls: ar Assay	26c. IF TESTEI Non-Molecular O Positive	D, WHAT WAS THE TESTING R Test Results:  Ondeterminate  Negative	RESULT?		ENES?	
☐ Carbapenemase Inactivation	Molecular Test Method  ☐ Automated Molecula ☐ Carba-R	ls: ar Assay	26c. IF TESTEI Non-Molecular O Positive () MOLECULAR T	D, WHAT WAS THE TESTING R Test Results:  Ondeterminate  Negative	RESULT?			
☐ Carbapenemase Inactivation Method (CIM) ☐ CPO Detect	Molecular Test Method  Automated Molecula  Carba-R  Check Points  MALDI-TOF MS	ls: ar Assay	26c. IF TESTEI Non-Molecular O Positive ( MOLECULAR T	D, WHAT WAS THE TESTING R Test Results:  Ondeterminate  Negative	RESULT?	○ Pos ○	Neg C	) Ind OUnk
☐ Carbapenemase Inactivation Method (CIM) ☐ CPO Detect ☐ Disk Diffusion/ROSCO Disk E-test	Molecular Test Method  Automated Molecula  Carba-R  Check Points  MALDI-TOF MS  Next Generation Nuc	ls: ar Assay	26c. IF TESTEI Non-Molecular O Positive O MOLECULAR T  NDM  KPC	D, WHAT WAS THE TESTING R Test Results:  OIndeterminate O Negative EST RESULTS:	RESULT?	O Pos O O Pos O	Neg C	Ind OUnk
☐ Carbapenemase Inactivation Method (CIM) ☐ CPO Detect ☐ Disk Diffusion/ROSCO Disk E-test ☐ Modified Carbapenemase Inactivation Method (mCIM)	Molecular Test Method  Automated Molecula  Carba-R  Check Points  MALDI-TOF MS  Next Generation Nucles  Acid Sequencing	ls: ar Assay	26c. IF TESTEI Non-Molecular O Positive O MOLECULAR T  NDM  KPC	D, WHAT WAS THE TESTING R Test Results:  Ondeterminate  Negative	RESULT?	○ Pos ○ ○ ○ Pos ○ ○ Pos ○	Neg C Neg C	
☐ Carbapenemase Inactivation Method (CIM) ☐ CPO Detect ☐ Disk Diffusion/ROSCO Disk E-test ☐ Modified Carbapenemase Inactivation Method (mCIM) ☐ Modified Hodge Test (MHT)	Molecular Test Method  Automated Molecular Carba-R  Check Points  MALDI-TOF MS  Next Generation Nuclear Acid Sequencing  PCR  Streck ARM-D	ls: ar Assay	26c. IF TESTEI Non-Molecular Positive  MOLECULAR T  NDM  KPC  OXA (speci	D, WHAT WAS THE TESTING R Test Results:  OIndeterminate O Negative EST RESULTS:	RESULT?	<ul><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ O</li></ul>	Neg ( Neg ( Neg ( Neg (	Ind OUnk
☐ Carbapenemase Inactivation Method (CIM) ☐ CPO Detect ☐ Disk Diffusion/ROSCO Disk E-test ☐ Modified Carbapenemase Inactivation Method (mCIM)	Molecular Test Method  Automated Molecula  Carba-R  Check Points  MALDI-TOF MS  Next Generation Nucles  Acid Sequencing	ls: ar Assay	26c. IF TESTEI Non-Molecular O Positive MOLECULAR T NDM KPC OXA (speci	D, WHAT WAS THE TESTING R Test Results:  OIndeterminate O Negative EST RESULTS:	RESULT?	<ul><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li></ul>	Neg C Neg C Neg C Neg C	Ind OUnk Ind OUnk Ind OUnk Ounk
☐ Carbapenemase Inactivation Method (CIM) ☐ CPO Detect ☐ Disk Diffusion/ROSCO Disk E-test ☐ Modified Carbapenemase ☐ Inactivation Method (mCIM) ☐ Modified Hodge Test (MHT) ☐ RAPIDEC	Molecular Test Method  Automated Molecular Carba-R  Check Points  MALDI-TOF MS  Next Generation Nuclear Acid Sequencing  PCR  Streck ARM-D	ls: ar Assay	26c. IF TESTEI Non-Molecular O Positive MOLECULAR T NDM KPC OXA (speci	D, WHAT WAS THE TESTING F Test Results: OIndeterminate  O Negative EST RESULTS:	RESULT?	<ul><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li><li>○ Pos</li></ul>	Neg C Neg C Neg C Neg C	Ind OUnk Ind OUnk Ind OUnk Ind OUnk Ind OUnk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	Is: ar Assay  cleic  27b. IF TESTED, V (Check all that ag	26c. IF TESTEI Non-Molecular Positive MOLECULAR T NDM KPC OXA (speci	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	RESULT?	O Pos O	Neg C Neg C Neg C Neg C Neg C	Ind OUnk Ind OUnk Ind OUnk Ind OUnk Ind OUnk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	Is: ar Assay  cleic  27b. IF TESTED, V (Check all that ap	26c. IF TESTEI Non-Molecular Positive MOLECULAR T NDM KPC OXA (speci	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	RESULT?  Dunknown  27c. IF Ti	O Pos O	Neg C Neg C Neg C Neg C Neg C	Olnd OUnk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No ○ Laboratory not testing	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	Is: ar Assay  cleic  27b. IF TESTED, V (Check all that ap	26c. IF TESTEINOn-Molecular O Positive MOLECULAR T NDM KPC OXA (speci	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	Pos	O Pos O O O O Pos O O O O Pos O O O O O Pos O O O O O O O O O O O O O O O O O O O	Neg C Neg C Neg C Neg C Neg C	Olnd OUnk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	27b. IF TESTED, V (Check all that ap Broth Microdilut ESBL well	26c. IF TESTEINOn-Molecular O Positive MOLECULAR T NDM KPC OXA (speci	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	27c. IF TI	O Pos O O O O Pos O O O O Pos O O O O O Pos O O O O O O O O O O O O O O O O O O O	Neg C Neg C Neg C Neg C Neg C	Olnd OUnk Ounk Ounk Ounk Ounk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No ○ Laboratory not testing	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	27b. IF TESTED, V (Check all that ap  Broth Microdilut  ESBL well  Expert rule (A	26c. IF TESTEI Non-Molecular Positive MOLECULAR T NDM KPC OXA (speci VIM IMP Other carb WHAT TESTING poply): tion (ATI detecti	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	27c. IF TI  Pos  Pos  Pos  Pos	O Pos O Pos O Pos O Pos O Pos O Pos O Neg O Neg	Neg C Neg C Neg C Neg C Neg C Neg C O Ind O Ind O Ind	Olnd OUnk Ounk Ounk Ounk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No ○ Laboratory not testing	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	27b. IF TESTED, V (Check all that ap Broth Microdilut ESBL well Expert rule (A) Unknown	26c. IF TESTEI Non-Molecular Positive MOLECULAR T NDM KPC OXA (speci VIM IMP Other carb WHAT TESTING poply): tion (ATI detecti	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	27c. IF TI O Pos O Pos O Pos O Pos	O Pos	Neg C Neg C Neg C Neg C Neg C Neg C Olind Olind Olind	Olnd OUnk Ounk Ounk Ounk Ounk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No ○ Laboratory not testing	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	27b. IF TESTED, V (Check all that ap  Broth Microdilut  ESBL well  Expert rule (A  Unknown  Broth Microdilut  Disk Diffusion	26c. IF TESTEI Non-Molecular Positive MOLECULAR T NDM KPC OXA (speci VIM IMP Other carb WHAT TESTING poply): tion (ATI detecti	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	27c. IF TI  Pos  Pos  Pos  Pos  Pos  Pos  Pos  Po	Pos O Pos O Pos O Pos O Pos O Pos O Neg Neg Neg Neg Neg	Neg C Ind O Ind O Ind O Ind	Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Ounk Ounk Ounk Ounk Ounk
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No ○ Laboratory not testing	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	27b. IF TESTED, V (Check all that ap  Broth Microdilut  ESBL well  Expert rule (A  Unknown  Broth Microdilut  Disk Diffusion  E-test	26c. IF TESTEI Non-Molecular O Positive MOLECULAR T NDM KPC OXA (speci VIM IMP Other carb  WHAT TESTING Oply): tion (ATI detecti ATI flag) tion (Manual)	D, WHAT WAS THE TESTING FOR TH	27c. IF TI  O Pos O Pos O Pos O Pos O Pos	Pos O Neg O Neg O Neg O Neg O Neg O Neg	Neg C O Ind O Ind O Ind O Ind O Ind	Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Ounk Ounk Ounk Ounk Ounk Ounk Ounk Ou
□ Carbapenemase Inactivation Method (CIM) □ CPO Detect □ Disk Diffusion/ROSCO Disk E-test □ Modified Carbapenemase Inactivation Method (mCIM) □ Modified Hodge Test (MHT) □ RAPIDEC □ Other (specify): □ Unknown  27a. WAS THE INCIDENT SPECIME PRODUCTION OR OTHER BETA-LA ○ Yes ○ No ○ Laboratory not testing	Molecular Test Method  Automated Molecular Carba-R Check Points MALDI-TOF MS Next Generation Nucacid Sequencing PCR Streck ARM-D Other (specify): Unknown	27b. IF TESTED, V (Check all that ap  Broth Microdilut  ESBL well  Expert rule (A  Unknown  Broth Microdilut  Disk Diffusion  E-test  Molecular test (s	26c. IF TESTEI Non-Molecular O Positive MOLECULAR T NDM KPC OXA (speci VIM IMP Other carb WHAT TESTING poply): tion (ATI detecti ATI flag) tion (Manual)	D, WHAT WAS THE TESTING RETEST RESULTS:  Ondeterminate Onegative EST RESULTS:  fy):  apenemase gene (specify):  is METHOD WAS USED?	27c. IF TI  Pos  Pos  Pos  Pos  Pos  Pos  Pos  Po	O Pos	Neg C Ind O Ind O Ind O Ind	Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Olnd OUnk Ounk Ounk Ounk Ounk Ounk Ounk

## 28. SUSCEPTIBILITY RESULTS: Please complete the table below based on the results from the data source (Accelerate Pheno System, E-test, Kirby Bauer, Microscan, Phoenix, Sensititre, Vitek, or Medical Record). Data source: Data source: Data source: MIC or zone MIC or zone MIC or zone Interpretation Interpretation Interpretation Antibiotic diameter diameter diameter Amikacin Amoxicillin/Clavulanate Ampicillin Ampicillin/Sulbactam Aztreonam Cefazolin Cefepime Cefiderocol Cefotaxime Cefoxitin Ceftazidime Ceftazidime/Avibactam Ceftolozane/Tazobactam Ceftriaxone Cephalothin Ciprofloxacin Colistin Doripenem Doxycycline Eravacycline Ertapenem **Fosfomycin** Gentamicin Imipenem Imipenem-relebactam Levofloxacin Meropenem Meropenem-vaborbactam Minocycline Moxifloxacin Nitrofurantoin Om Pip Pla Po Rif Te Tig То Tri sul

nadacycline			
peracillin/Tazobactam			
azomicin			
lymyxin B			
fampin			
tracycline			
gcycline			
bramycin			
methoprim- Ifamethoxazole			
29a. WAS THE CASE FIR IDENTIFIED THROUGH A OYes ONo 29e. COMMENTS:	29b. CRF STATUS:  O Complete O Pending O Chart unavailable after O Complete - pending do	29c. SO INITIALS:	29d. DATE OF ABSTRACTION: (mm/dd/yyyy)
			Page 4